Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;9(3):666-674.
doi: 10.21037/jtd.2017.02.90.

Impact of lymph node management on resectable non-small cell lung cancer patients

Affiliations

Impact of lymph node management on resectable non-small cell lung cancer patients

Apichat Tantraworasin et al. J Thorac Dis. 2017 Mar.

Abstract

Background: A surgical lung resection with systematic mediastinal lymph node (LN) dissection is recommended by the National Comprehensive Cancer Network guideline. However, the effective number of dissected LNs, stations and positivity is still controversial. The aim of this study is to identify the impact of total numbers, LN stations and positivity of dissected LNs on tumor recurrence and overall death in resectable non-small cell lung cancer (NSCLC).

Methods: This prognostic study used a retrospective data collection design. Adult patients with clinical resectable NSCLC who underwent pulmonary resection and mediastinal lymphadenectomy at Chiang Mai University between June 2000 and June 2012 were enrolled in this study. A multilevel mixed-effects parametric survival model was used to identify the effect of numbers, LN stations and positivity of dissected LNs to tumor recurrence and mortality.

Results: The average number of dissected LNs was 22.7±12.8. Tumor recurrence was found in 51.3% and overall mortality was 43.3%. The number of dissected LNs was a prognostic factor for tumor recurrence [HR 0.98, 95% confidence interval (CI): 0.96-0.99]. There was a significant difference at the cut-pointed value of 11 dissected LNs for tumor recurrence (HR 2.22, 95% CI: 1.26-3.92). Dissection less than 11 nodes and less than 5 stations indicated a poor prognostic factor for tumor recurrence: for 3-4 stations (HR 3.01, 95% CI: 1.22-7.42) and for 1-2 stations (HR 1.96, 95% CI: 1.04-3.72). The positivity of dissected LNs was also a prognostic factor for tumor recurrence and overall mortality (HR 1.01, 95% CI: 1.01-1.02 and HR 1.01, 95% CI: 1.01-1.03, respectively).

Conclusions: Eleven or more LN dissection with at least 5 stations influenced recurrent-free survival. Systematic LN dissection (SLND) should be performed not only to identify the positivity of dissected LNs but also to determine an accurate tumor nodal stage. A larger cohort should be further conducted to support these findings.

Keywords: Mediastinal lymphadenectomy; lung cancer; mediastinal node dissection; positivity; pulmonary resection.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Correlation between positivity of dissected lymph nodes and recurrent rate and recurrent time (A), and mortality rate and survival time (B).
Figure 2
Figure 2
Recurrent-free survival curves according to the cut-point of dissected LNs of 11 LNs. (A) overall; (B) stage I; (C) stage II; (D) stage III, analyzed by mixed-effects Weibull regression.
Figure S1
Figure S1
Unadjusted Kaplan-Meier curve demonstrated recurrent-free survival curves according to the cut-point of dissected LNs of 11 LNs. (A) Overall stage; (B) stage I; (C) stage II; (D) stage III.

References

    1. Schapira MM, Aggarwal C, Akers S, et al. How Patients View Lung Cancer Screening. The Role of Uncertainty in Medical Decision Making. Ann Am Thorac Soc 2016;13:1969-76. 10.1513/AnnalsATS.201604-290OC - DOI - PMC - PubMed
    1. Zhou H, Tapias LF, Gaissert HA, et al. Lymph Node Assessment and Impact on Survival in Video-Assisted Thoracoscopic Lobectomy or Segmentectomy. Ann Thorac Surg 2015;100:910-6. 10.1016/j.athoracsur.2015.04.034 - DOI - PubMed
    1. Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:234S-242S. - PubMed
    1. Wu N, Yan S, Lv C, et al. Comparison of systematic mediastinal lymph node dissection versus systematic sampling for lung cancer staging and completeness of surgery. J Surg Res 2011;171:e169-73. 10.1016/j.jss.2011.04.045 - DOI - PubMed
    1. Keller SM, Adak S, Wagner H, et al. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group. Ann Thorac Surg 2000;70:358-65; discussion 365-6. 10.1016/S0003-4975(00)01673-8 - DOI - PubMed

LinkOut - more resources